miércoles, 21 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· January 8, 2026

Croissance organique de +6,0 % au premier trimestre 2026 - Confirmation des objectifs annuels

View original at globenewswire.com
Croissance organique de +6,0 % au premier trimestre 2026 - Confirmation des objectifs annuels Communiqué de presse Roubaix, 8 janvier 2026 Croissance organique de +6,0 % au premier trimestre 2026 Confirmation des objectifs annuels Chiffre d’affaires par segment de produits (en millions d'euros)2025 1er trimestre2026 1e…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Company is structured toward new target of €2 billion revenue

    80% confidence

  • Net revenue retention rate reached 105% on a comparable basis

    80% confidence

  • Q1 revenue exceeded €275 million with 6.0% organic growth

    80% confidence

  • OVHcloud confirms all FY2026 objectives including positive Free Cash-Flow generation

    80% confidence

  • Supply chain optimization initiated in 2025 allows continued service delivery while respecting investment envelope

    80% confidence

  • Group maintained operational and financial discipline, particularly on general and administrative expense control

    80% confidence

Citado en estos reportajes de Via News

Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Q4 2026 Biopharma Catalyst Crunch: Late-Stage Readouts and Regulatory Milestones Converge on the Ivonescimab PDUFA Date
October 2026 is dense with clinical and regulatory news. Phase 3 trials hit primary endpoints (ALOFT-IPF, RESTORE-3), long-term data came out (MIUDELLA at 6 years, QUILT-3.032), and the FDA accepted Roche's vamikibart BLA. Scholar Rock resubmitted its apitegromab MAA to the EMA. The next catalysts are ESMO 2026 (Oct 23) and the Nov 14 FDA PDUFA date for ivonescimab, followed by Maritime-1 primary completion in January 2027. The speculative QAIAx items (QIII pilot, microcities patent) are a weak, tangential thread with little financial substance.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,406 documentos fuente archivados
Consulta estos datos → isubstrate.com